RxDoctor Payments Data

Nathan Spence, MD

Interventional Cardiology · Spokane, WANPI 1821231986

Payments from drug & device makers

$885in general payments, 2019–2025

Across 9 payments — averaging $98.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$825
  • Pfizer$39
  • Kestra Medical Technology Services, Inc.$21

What the payments were for

  • Travel & lodging$78889%
  • Food & beverage$9811%

General payments by program year

19
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$885 in reported general payments places this provider in the 20th percentile of 125 interventional cardiology providers in Washington.

See all interventional cardiology providers in Washington

Medicare billing

Part B allowed, 2024
$364,959
Medicare patients
1,372
Services billed
3,426

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban524$519,273
XareltoRivaroxaban122$118,228
FarxigaDapagliflozin Propanediol97$81,923
Repatha SureclickEvolocumab100$76,858
EntrestoSacubitril/Valsartan66$70,403
Praluent PenAlirocumab89$52,430
JardianceEmpagliflozin25$19,148
Repatha SyringeEvolocumab33$17,091
Torsemide504$6,678
Atorvastatin Calcium556$6,369
Metoprolol Succinate465$6,055
Potassium Chloride483$5,864
Rosuvastatin Calcium309$5,087
Ranolazine ErRanolazine20$3,869
Lisinopril421$3,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$39$519,273524 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 125 interventional cardiology providers in Washington.

Other interventional cardiology in Spokane

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →